The company exceeded RON1 billion revenue for the first time in 2024.
The turnover tax, fiscal instability, and the difficulty in finding human resources are the main challenges in the market for Bioeel.
“The labor market—identifying and retaining skilled labor, inflation and operating costs, rising fuel, energy, and labor costs are eroding profit margins, in our case in a strictly regulated area of the prices of the products we distribute. Market concentration and segmentation have the effect of limiting access and undersizing the development space for independent companies,” Bioeel representatives told ZF.
Bioeel specializes in production and distribution of medicines, with two production facilities in Targu-Mures and several medicine warehouses in Targu-Mures, Timisoara, and Ploiesti.
The company is 50% held by businessman Albert Attila, who is also its manager, while the remaining 50% is held by Scheftsik de Szolnok Jean Stephan Georges, a French citizen.
The minimum turnover tax for businesses exceeding EUR50 million was also a problem for pharmaceutical companies, including Bioeel.
(English version by Loredana Fratila-Cristescu)